Integrated Chemistry Analyzers Offer Full Portfolio of Oncology Tests

Integrated chemistry analyzers offer a full portfolio of oncology tests including new markers for ovarian, breast, and pancreatic cancer.

The Dimension Vista systems employ LOCI technology, offering high sensitivity, quick reaction times, low sample volumes, and simple homogeneous processing with no washing or separation steps.

The integration of LOCI advanced chemiluminescence technology provides laboratories access to high sensitivity oncology testing on an integrated chemistry platform. The technology uses an oxygen channeling mechanism that provides unlimited signal generation, eliminating the need for trigger reagents and reducing a potential source of error. In addition, the technology requires fewer reaction steps resulting in fast turnaround times for all assays.

Siemens Healthcare Diagnostics' (Deerfield, IL, USA) LOCI CA 125II, CA 15-3 and CA 19-9 have been CE Marked for use on the Dimension Vista Intelligent Lab Systems, which now offer a complete panel of oncology assays outside the United States. The new cancer markers are currently under review by the U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA).

CA 125II is used as an aid for monitoring disease progress or response to therapy for patients with recurrent or residual epithelial ovarian cancer. When combined with other clinical and diagnostics procedures, CA 15-3 can be utilized as an aid in the management of previously treated stage II and III breast cancer patients and for monitoring response to therapy in metastatic breast cancer patients. CA 19-9 can be helpful in the management of patients diagnosed with cancers of the exocrine pancreas.

The new markers are part of a test menu of more than 120 assays on the Dimension Vista systems that offer test panels for cancer, anemia, cardiac disease, thyroid disorders, therapeutic drug monitoring, protein testing, drugs-of-abuse testing, and routine and specialty chemistry testing--all on one system and using a single patient sample.

"We are committed to providing a comprehensive portfolio of oncology assays that are trusted by cancer centers and institutions worldwide,” said David Hickey, executive vice president, central laboratory and global research and development, Siemens Healthcare Diagnostics. "This latest addition to our portfolio provides our customers with a complete test menu of highly sensitive cancer markers on a single integrated chemistry instrument.”

Related Links:
Siemens Healthcare Diagnostics
U.S. Food and Drug Administration